DIRS.INFO The most relevant business & tech news

☆ Counterfeit Botox has been found in several states. Here’s what consumers should know.
▼ + stars: | 2024-04-16 | by ( Jacqueline Howard | ) edition.cnn.com time to read: +11 min

CNN —The US Food and Drug Administration is warning that dangerous counterfeit versions of Botox have been identified in multiple states, putting the safety of consumers at risk. The incidents of counterfeit Botox being administered to consumers appear to be connected to products that have been purchased from unlicensed sources and then administered by either unlicensed or licensed providers. The counterfeit Botox products may be identified by the lot number C3709C3 found on the outer carton and vial, the FDA said. Counterfeit botox has been found in several states. Most often, when counterfeit Botox is sold, “the injector knows they’re purchasing something counterfeit,” Sung said.

Persons: Washington –, Botox, Lavanya Krishnan, Arya Derm, ” Krishnan, Krishnan, Allergan, ”, “, Jimmy Sung, you’re, can’t, ” Sung, Michael Cameron, Cameron, ” Cameron, Sung, “ I’m, I’ve, Steven Williams, ” Williams, Dr, Sanjay Gupta, Cynthia Elliott, ” Elliott Organizations: CNN, Food and Drug Administration, FDA, US Centers for Disease Control, CDC, American Board of Cosmetic, Revance Therapeutics, Merz Aesthetics, Tribeca Aesthetics, Cameron Dermatology, Mount Sinai Health, American Society of Plastic Surgeons, “, CNN Health Locations: – Colorado, Florida , Illinois , Kentucky , Nebraska , New Jersey , New York , Tennessee, San Francisco, United States, New York City, New York, Florida

☆ Linda Evangelista has no desire to date
▼ + stars: | 2023-11-27 | by ( Lisa Respers France | ) edition.cnn.com time to read: +2 min

CNN —Linda Evangelista still turns heads as one of the world’s first supermodels, but she says she’s “not interested” in dating. In an interview with the Sunday Times, the 58-year-old was asked about it and explained why she has no desire to be involved with anyone right now. In her latest interview, Evangelista said therapy has helped her even as the lumps on her body are softening. I’m not completely rid of it, but I work hard at getting rid of the guilt and the shame. Remember when you used to laugh all the time?” Evangelista recalled her son asking her.

Persons: Linda Evangelista, she’s “, ”, “, ” Evangelista, Evangelista, Augie, François, Henri Pinault Organizations: CNN, Sunday Times Locations: CoolSculpting

☆ Exclusive: Activist investor Elliott targets drugmaker BioMarin -sources
▼ + stars: | 2023-11-07 | by ( Svea Herbst-Bayliss | ) www.reuters.com time to read: +3 min

NEW YORK, Nov 7 (Reuters) - Activist investor Elliott Investment Management has built a stake in BioMarin Pharmaceutical (BMRN.O) and has been in discussions with the biotechnology company for months about its future, according to two people familiar with the matter. Elliott declined to comment, while a representative for BioMarin did not immediately respond to a request for comment. BioMarin shares rose 12% to $85.36 on the news in morning trading in New York on Tuesday. Prior to news of Elliott's engagement, BioMarin shares were down 24% year-to-date, significantly underperforming the iShares Biotechnology ETF (IBB.O), which is down 8.6%. Elliott also successfully pushed for drug makers Alexion Pharma (AZN.L) and Allergan (ABBV.N) to be sold.

Persons: Elliott, BioMarin, hemophilia, Jean, Jacques Bienaime, Alexander Hardy, Jefferies, Bienaime, Harvey, Richard Meier, Svea Herbst, Bayliss, Jamie Freed Organizations: Investment Management, BioMarin Pharmaceutical, Biotechnology, Alexion Pharma, Svea, Thomson Locations: BioMarin, San Rafael , California, West Palm Beach , Florida, New York

☆ Pfizer to raise $31 bln for Seagen takeover in largest debt offering
▼ + stars: | 2023-05-17 | by ( ) www.reuters.com time to read: +1 min

May 16 (Reuters) - Pfizer Inc (PFE.N) is planning to raise $31 billion through its largest debt offering to finance its proposed acquisition of Seagen Inc (SGEN.O), the drugmaker said late on Tuesday. Rival Abbvie Inc (ABBV.N) had in 2019 made a $30 billion debt offering, which was used to finance its $63 billion buyout of Botox maker Allergan. The amount is more than double that of Pfizer's 2009 debt raise of $13.5 billion. The debt offering, which would be in eight tranches, is expected to close on May 19. Yield to maturity on Pfizer's 10-year bonds would be 125 basis points higher than the benchmark risk-free U.S. 10-year Treasury .

☆ AbbVie's weak newer drug sales fan worries as Humira faces rivals
▼ + stars: | 2023-04-27 | by ( ) www.reuters.com time to read: +2 min

April 27 (Reuters) - AbbVie Inc (ABBV.N) on Thursday missed quarterly revenue estimates for its newer treatments, fueling concerns over the drugmaker's attempts to cushion the blow to sales from blockbuster Humira losing patent exclusivity. The company's shares tumbled 6% in premarket trade as investors shrugged off a raised annual profit forecast. In the first quarter, Humira recorded sales of $3.54 billion, compared with analysts' average estimate of $3.58 billion. That helped Abbvie beat sales expectations. AbbVie had trimmed its full-year profit expectations earlier this month by 8 cents, citing a $150 million hit from acquired in-process research and development (IPR&D) and milestone expenses.

☆ The Pfizer-Seagen deal has a hidden $1 billion warning for workers
▼ + stars: | 2023-03-13 | by ( Yeji Jesse Lee | ) www.businessinsider.com time to read: +2 min

While the deal bolsters Pfizer's cancer portfolio, it also mean cuts focused on "eliminating duplication"Pfizer said it is aiming for $1 billion in "cost efficiencies" within 3 years of the deal. Pharmaceutical giant Pfizer said on Monday that it would acquire drug developer Seagen in a massive $43 billion deal that would bolster its oncology portfolio. The acquisition is the largest biopharma deal since 2019 when AbbVie acquired Allergan for $63 billion, according to Stat News. Namely, Pfizer is aiming for $1 billion in "cost efficiencies" within three years of the deal closing, which could mean job cuts. Pfizer's deal for Seagen is expected to close in late 2023 or early 2024.

Takeda CFO Costa Saroukos in a 2018 picture. Mr. Saroukos joined Takeda in 2015 as CFO of Takeda’s European and Canadian operations before he was elevated to global CFO in 2018. WSJ: What did you learn from your deal-integration experiences that helped with the Takeda and Shire integration? ” — Costa Saroukos, CFO of TakedaAnother reason speed is important is to avoid losing talent. We broadened CFOinUrpocket to be used globally across 80 countries for the combined Takeda and Shire offices.

☆ Returning pharma CEO has one prescription: M&A
▼ + stars: | 2023-02-17 | by ( Robert Cyran | ) www.reuters.com time to read: +3 min

NEW YORK, Feb 17 (Reuters Breakingviews) - Brent Saunders is back in charge of a pharmaceutical company, which usually means one thing: M&A. The buyer, Actavis, appointed Saunders CEO of the combined company. Bausch + Lomb remains a subsidiary of Bausch Health, which owns nearly 90% of the shares. Considering Bausch Health’s stake in Bausch + Lomb is worth more than $5 billion, the implication is that bondholders are in charge. Saunders was CEO of Bausch + Lomb from 2010 until 2013, when it was acquired by Valeant Pharmaceuticals.

☆ Buyers swoop in to help the S&P 500 shake off earlier losses — listen to the 'Homestretch'
▼ + stars: | 2023-02-15 | by ( ) www.cnbc.com time to read: +17 min

I LIKE A STOCK THAT'S DE-RISKEDWHICH IS WHY I THINK EMERSON ISA GREAT BUY. I THINK THAT'S A GOOD STRATEGY. JEFF, I DON'T KNOW HOW ELSE TOPUT IT. I DON'T THINK ANYONE SHOULD SELLTHIS ON THE NOTION THAT THERE'SAN ANALYST WHO MISSED THE WHOLETHING IS SAYING SELLING. >> THAT'S GREAT.

☆ Top 10 things the Club is watching in the stock market Wednesday: Retail sales up, stocks dip, Airbnb soars
▼ + stars: | 2023-02-15 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

Retail sales for January came in higher than expected. Remember, retail sales are not adjusted for inflation, which of course remains elevated but growing at a slower rate in recent months. Earnings per share (EPS) of 48 cents versus 25 cents expected. Kraft Heinz (KHC) EPS beats: 85 cents versus 78 cents expected. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

☆ This dividend stock fund is beating the market. Here's its strategy and positions
▼ + stars: | 2023-01-10 | by ( Michelle Fox | ) www.cnbc.com time to read: +6 min

The firm's Integrity Dividend Harvest Fund ended 2022 down just 1.45%, while the broader market saw its worst year since 2008. So far in 2023, Integrity Dividend has gained more than 5%, while the S & P is up only a little more than 1%. IDHIX 1Y mountain Integrity Dividend Harvest I outperformed the S & P 500 in 2022. The stock, which gained more than 19% last year, has a 3.65% dividend yield. "They're pointing to 6% to 7% long-term annual earnings growth, along with dividends growing in lockstep to their earnings," Radke said.

Nov 22 (Reuters) - Teva Pharmaceutical Industries Ltd (TEVA.TA) and AbbVie Inc (ABBV.N) have finalized the terms of settlements worth more than $6.6 billion to resolve thousands of lawsuits by U.S. state and local governments over the marketing of opioid painkillers, the companies and lawyers for the governments said Tuesday. Under the deals, first announced in July, Israel-based Teva will pay up to $4.25 billion, including a supply of the overdose drug naloxone. AbbVie will pay up to $2.37 billion. The final amounts of the settlements will depend on how many state and local governments opt into them. The sprawling litigation over opioids, which began in 2017, has yielded more than $40 billion in settlements with drugmakers, distributors and pharmacy chains.

The following are major companies that were accused of contributing to the crisis, and settlements or judgments involving those companies. Teva Pharmaceutical Industries Ltd (TEVA.TA)-In November, finalized claims nationwide for $4.25 billion, some of which is to be paid as a supply of the overdose-reversing drug naloxone. AbbVie Inc (ABBV.N)-In November, finalized a $2.37 billion nationwide settlement resolving claims against Allergan, a company it acquired in 2020. Endo International Plc (ENDPQ.PK)-Reached a $450 million settlement with more than 30 states as part of a bankruptcy filing in August. Mallinckrodt Plc (MNK.A)-Reached a $1.7 billion nationwide settlement as part of its bankruptcy reorganization plan, approved in February.

AbbVie and lawyers for the plaintiffs did not immediately respond to requests for comment. The lawsuit claims the settlements were so-called "pay for delay" deals that violated competition laws in 30 states and resulted in higher prices. The generic companies previously settled with the health plans for a combined $2 million. Allergan previously reached a $750 million settlement of antitrust allegations brought by direct purchasers of Namenda, such as drug distributors. The case is In re Namenda Indirect Purchaser Antitrust Litigation, U.S. District Court, Southern District of New York, No.

☆ The 'next Warren Buffett' curse: Sam Bankman-Fried is the latest market icon to fall after being compared to the legendary investor
▼ + stars: | 2022-11-12 | by ( Matthew Fox | ) www.businessinsider.com time to read: +5 min

The Warren Buffett curse is alive and well following the collapse of Sam Bankman-Fried and his crypto exchange FTX. Fortune magazine asked if Bankman-Fried was the next Warren Buffett in an August profile. Fortune put Bankman-Fried on the front page of its August issue, asking readers if he was in fact the next Warren Buffett? Several of Palihapitiya's SPAC companies soared in value amid the SPAC boom of 2020 and the early months of 2021. Palihapitiya was often compared to Buffett by market participants, and Brown called the investor "the new Buffett" on a podcast in January 2021.

☆ The House That Botox Built: Ex-Allergan CEO Lists Miami Home for $21.9 Million
▼ + stars: | 2022-09-19 | by ( E.B. Solomont | ) www.wsj.com time to read: 1 min

Be the first to know about the biggest and best luxury home sales and listings by signing up for our Mansion Deals email alert. Brent Saunders , former CEO of the Botox maker Allergan, is listing his contemporary Miami home for $21.9 million.

☆ Here’s our September rapid-fire update on all 33 stocks in Cramer’s Charitable Trust portfolio
▼ + stars: | 2022-09-15 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +11 min

Here's a rapid-fire update on every stock in the CNBC Investing Club portfolio. Halliburton (HAL) — The only energy stock in the portfolio that we haven't trimmed in recent weeks. (See here for a full list of the stocks Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Search resuls for: "Allergan"

17 mentions found